AR124295A1 - Agonistas duales del receptor de amilina y calcitonina y usos de los mismos - Google Patents
Agonistas duales del receptor de amilina y calcitonina y usos de los mismosInfo
- Publication number
- AR124295A1 AR124295A1 ARP210103420A ARP210103420A AR124295A1 AR 124295 A1 AR124295 A1 AR 124295A1 AR P210103420 A ARP210103420 A AR P210103420A AR P210103420 A ARP210103420 A AR P210103420A AR 124295 A1 AR124295 A1 AR 124295A1
- Authority
- AR
- Argentina
- Prior art keywords
- compounds
- amylin
- calcitonin receptor
- dual agonists
- dyslipidemia
- Prior art date
Links
- 108010001789 Calcitonin Receptors Proteins 0.000 title abstract 2
- 239000000556 agonist Substances 0.000 title abstract 2
- 108091005466 amylin receptors Proteins 0.000 title abstract 2
- 102100038520 Calcitonin receptor Human genes 0.000 title 1
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 title 1
- 230000009977 dual effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 2
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 2
- 208000008589 Obesity Diseases 0.000 abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 abstract 2
- 235000020824 obesity Nutrition 0.000 abstract 2
- -1 2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl Chemical group 0.000 abstract 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 102000055006 Calcitonin Human genes 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 230000037396 body weight Effects 0.000 abstract 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 abstract 1
- 229960004015 calcitonin Drugs 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000037406 food intake Effects 0.000 abstract 1
- 235000012631 food intake Nutrition 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 150000003626 triacylglycerols Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/585—Calcitonins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
- C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Emergency Medicine (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Child & Adolescent Psychology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente descripción se refiere al campo de la medicina. Más particularmente, la descripción se encuentra en el campo del tratamiento de la diabetes, la obesidad y/o la dislipidemia. La descripción se refiere a compuestos que son agonistas tanto de los receptores de calcitonina como de amilina y pueden reducir la ingesta de alimentos, el peso corporal, la glucosa y/o los triglicéridos, por lo que pueden usarse para tratar la diabetes, la obesidad y/o la dislipidemia. La presente descripción también incluye composiciones farmacéuticas que contienen tales compuestos y usos terapéuticos de tales compuestos y composiciones. Reivindicación 1: Un compuesto que comprende: Acetil-ASHLSTAVLGK((2-[2-(2-Amino-etoxi)-etoxi]-acetil)₂-(g-Glu)-CO-(CH₂)₁₈-CO₂H)LS-Aib-ELHKLEDYPRTDVGAESP-NH₂ (SEQ ID Nº 2) o una sal farmacéuticamente aceptable de este.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063127186P | 2020-12-18 | 2020-12-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR124295A1 true AR124295A1 (es) | 2023-03-15 |
Family
ID=80113494
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210103420A AR124295A1 (es) | 2020-12-18 | 2021-12-09 | Agonistas duales del receptor de amilina y calcitonina y usos de los mismos |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US11541123B2 (es) |
| EP (1) | EP4262977A1 (es) |
| JP (1) | JP2024500163A (es) |
| KR (1) | KR20230146004A (es) |
| CN (1) | CN117729941A (es) |
| AR (1) | AR124295A1 (es) |
| AU (1) | AU2021401314B2 (es) |
| CA (1) | CA3201167A1 (es) |
| CL (1) | CL2023001744A1 (es) |
| CO (1) | CO2023007807A2 (es) |
| CR (1) | CR20230252A (es) |
| DO (1) | DOP2023000121A (es) |
| EC (1) | ECSP23045245A (es) |
| IL (1) | IL303743A (es) |
| MX (1) | MX2023007240A (es) |
| PE (1) | PE20231560A1 (es) |
| TW (3) | TW202317174A (es) |
| WO (1) | WO2022133187A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3204051A1 (en) | 2021-01-20 | 2022-07-28 | Brian Lian | Compositions and methods for the treatment of metabolic and liver disorders |
| WO2024050289A1 (en) | 2022-08-29 | 2024-03-07 | Eli Lilly And Company | Compositions for oral delivery |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4639510A (en) * | 1985-10-04 | 1987-01-27 | Armour Pharmaceutical Company | (1-S-acetamidomethyl cysteine, 7-alanine)calcitonin |
| JP5753097B2 (ja) | 2009-01-22 | 2015-07-22 | ユニジーン・ラボラトリーズ・インコーポレーテッド | 肥満の治療 |
| RS57152B1 (sr) | 2013-11-14 | 2018-07-31 | Keybioscience Ag | Mimetici kalcitonina za lečenje bolesti i poremećaja |
| EP3189071B1 (en) | 2014-09-04 | 2021-07-28 | Novo Nordisk A/S | Novel amylin and calcitonin receptor agonist |
| CA3178366A1 (en) * | 2018-07-23 | 2020-01-30 | Eli Lilly And Company | Gip/glp1 co-agonist compounds |
| GB201813678D0 (en) * | 2018-08-22 | 2018-10-03 | Keybioscience Ag | Acylated calcitonin mimetics |
| TWI764209B (zh) * | 2019-08-01 | 2022-05-11 | 美商美國禮來大藥廠 | Gipr促效劑化合物 |
-
2021
- 2021-12-09 TW TW112100098A patent/TW202317174A/zh unknown
- 2021-12-09 TW TW112100099A patent/TW202317173A/zh unknown
- 2021-12-09 AR ARP210103420A patent/AR124295A1/es unknown
- 2021-12-09 TW TW110146048A patent/TWI790850B/zh active
- 2021-12-17 PE PE2023001882A patent/PE20231560A1/es unknown
- 2021-12-17 CA CA3201167A patent/CA3201167A1/en active Pending
- 2021-12-17 KR KR1020237024537A patent/KR20230146004A/ko unknown
- 2021-12-17 IL IL303743A patent/IL303743A/en unknown
- 2021-12-17 US US17/554,022 patent/US11541123B2/en active Active
- 2021-12-17 CN CN202180084836.2A patent/CN117729941A/zh active Pending
- 2021-12-17 WO PCT/US2021/063990 patent/WO2022133187A1/en active Application Filing
- 2021-12-17 JP JP2023538041A patent/JP2024500163A/ja active Pending
- 2021-12-17 AU AU2021401314A patent/AU2021401314B2/en active Active
- 2021-12-17 EP EP21847828.7A patent/EP4262977A1/en active Pending
- 2021-12-17 CR CR20230252A patent/CR20230252A/es unknown
- 2021-12-17 MX MX2023007240A patent/MX2023007240A/es unknown
-
2022
- 2022-10-28 US US18/050,659 patent/US20230190945A1/en active Pending
- 2022-10-28 US US18/050,604 patent/US20230190944A1/en active Pending
-
2023
- 2023-06-14 DO DO2023000121A patent/DOP2023000121A/es unknown
- 2023-06-14 CL CL2023001744A patent/CL2023001744A1/es unknown
- 2023-06-15 CO CONC2023/0007807A patent/CO2023007807A2/es unknown
- 2023-06-16 EC ECSENADI202345245A patent/ECSP23045245A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TWI790850B (zh) | 2023-01-21 |
| JP2024500163A (ja) | 2024-01-04 |
| US20230190945A1 (en) | 2023-06-22 |
| ECSP23045245A (es) | 2023-07-31 |
| TW202317173A (zh) | 2023-05-01 |
| US11541123B2 (en) | 2023-01-03 |
| IL303743A (en) | 2023-08-01 |
| CR20230252A (es) | 2023-11-15 |
| PE20231560A1 (es) | 2023-10-03 |
| AU2021401314B2 (en) | 2024-07-04 |
| AU2021401314A1 (en) | 2023-06-29 |
| MX2023007240A (es) | 2023-09-04 |
| AU2021401314A9 (en) | 2024-07-04 |
| US20220193245A1 (en) | 2022-06-23 |
| TW202237172A (zh) | 2022-10-01 |
| TW202317174A (zh) | 2023-05-01 |
| EP4262977A1 (en) | 2023-10-25 |
| CO2023007807A2 (es) | 2023-08-28 |
| WO2022133187A1 (en) | 2022-06-23 |
| CL2023001744A1 (es) | 2024-01-19 |
| US20230190944A1 (en) | 2023-06-22 |
| KR20230146004A (ko) | 2023-10-18 |
| CN117729941A (zh) | 2024-03-19 |
| CA3201167A1 (en) | 2022-06-23 |
| DOP2023000121A (es) | 2023-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR124295A1 (es) | Agonistas duales del receptor de amilina y calcitonina y usos de los mismos | |
| Vangoitsenhoven et al. | GLP1 and cancer: friend or foe? | |
| ES2965283T1 (es) | Tratamiento de pacientes con hemoglobinuria paroxística nocturna mediante un inhibidor del complemento | |
| CO2023008866A2 (es) | Coagonistas de los receptores de glp-1 y amilina | |
| CL2022002813A1 (es) | Semaglutida para el tratamiento de esteatohepatitis no alcoholica. | |
| ECSP23066120A (es) | Agonistas del receptor de amilina de acción prolongada y usos de estos | |
| Goodwill et al. | Cardiovascular and hemodynamic effects of glucagon-like peptide-1 | |
| NZ610487A (en) | Treatment of cancer with elevated dosages of soluble fgfr1 fusion proteins | |
| da Silva Torres et al. | Rosiglitazone reverses cardiac adverse remodeling (fibrosis and vascularization) in perinatal low protein rat offspring | |
| ECSP19027578A (es) | Composición farmacéutica con antagonista del receptor de mineralocorticoides y su uso | |
| CO2023013976A2 (es) | Composición farmacéutica y uso del agonista dual del receptor de gip y glp-1 | |
| Matadamas-Martínez et al. | Characterisation of the in vitro activity of a Nitazoxanide-N-methyl-1H-benzimidazole hybrid molecule against albendazole and nitazoxanide susceptible and resistant strains of Giardia intestinalis and its in vivo giardicidal activity | |
| AR077427A1 (es) | Otamixaban para el tratamiento de pacientes con alteracion renal y de edad avanzada con infarto de miocardio sin elevacion del st | |
| CO2020001314A2 (es) | Tratamiento de pacientes con enfermedad de von willebrand grave que se someten a cirugía electiva mediante administración de vwf recombinante | |
| RU2696100C1 (ru) | Применение ксенона, иммобилизированного в носителе в средстве для повышения резистентности организма к гипоксии | |
| RU2015101218A (ru) | Способ лечения язв диабетической стопы, пролежневых язв, варикозных язв и сопутствующих осложнений | |
| US20230241078A1 (en) | Vanadyl and vanadate for use in reducing stress-induced metabolic derangement | |
| Kato et al. | In vitro effects of amodiaquine on paired Schistosoma mansoni adult worms at concentrations of less than 5 µg/mL | |
| Xia et al. | Research progress on the effects of glucagon like peptide-1 in metabolic cardiovascular disease | |
| Yang et al. | Mitochondrial Metabolism in Ischemic Heart Disease | |
| AR114012A1 (es) | Método para proporcionar terapia de celiprolol a un paciente | |
| Qiu | (302) Signaling events underlying the analgesic effect of propofol | |
| de Carvalho Guerra et al. | Os possíveis efeitos adversos dos análogos de GLP-1 em pessoas não-diabéticas e não-obesas | |
| 樊宽鲁 | Effect of gbpapentin on the expression of Nrf2 in dorsal root ganglion neurons of diabetic neuropathic pain rats | |
| CN106580988A (zh) | 一种治疗和预防肾纤维化药物及其应用 |